AstraZeneca PLC Total Voting Rights (5771Y)
January 02 2020 - 10:00AM
UK Regulatory
TIDMAZN
RNS Number : 5771Y
AstraZeneca PLC
02 January 2020
02 January 2020 15:00 GMT
Transparency Directive
Voting Rights and Capital
The following notification is made in accordance with the UK
Financial Conduct Authority's Disclosure and Transparency Rule
5.6.1. As at 31 December 2019 the issued share capital of
AstraZeneca PLC with voting rights is 1,312,137,976 ordinary shares
of US$0.25. No shares are held in Treasury. Therefore, the total
number of voting rights in AstraZeneca PLC is 1,312,137,976.
The above figure for the total number of voting rights may be
used by shareholders as the denominator for the calculations by
which they will determine if they are required to notify their
interest in, or a change to their interest in, AstraZeneca PLC
under the UK Financial Conduct Authority's Disclosure and
Transparency Rules.
About AstraZeneca
AstraZeneca (LSE/STO/NYSE: AZN) is a global, science-led
biopharmaceutical company that focuses on the discovery,
development and commercialisation of prescription medicines,
primarily for the treatment of diseases in three therapy areas -
Oncology, Cardiovascular, Renal and Metabolism, and Respiratory.
AstraZeneca operates in over 100 countries and its innovative
medicines are used by millions of patients worldwide. Please visit
astrazeneca.com and follow the Company on Twitter @AstraZeneca.
Media Relations
Gonzalo Viña +44 203 749 5916
Rob Skelding Oncology +44 203 749 5821
Rebecca Einhorn Oncology +1 301 518 4122
Matt Kent BioPharmaceuticals +44 203 749 5906
Jennifer Hursit Other +44 203 749 5762
Christina Malmberg Hägerstrand Sweden +46 8 552 53 106
Michele Meixell US +1 302 885 2677
Investor Relations
Thomas Kudsk Larsen +44 203 749 5712
Henry Wheeler Oncology +44 203 749 5797
Christer Gruvris BioPharmaceuticals (Cardiovascular, Metabolism) +44 203 749 5711
BioPharmaceuticals (Renal) Environmental, Social and
Nick Stone Governance +44 203 749 5716
BioPharmaceuticals (Respiratory)
Josie Afolabi Other medicines +44 203 749 5631
Finance
Craig Marks Fixed income +44 7881 615 764
Corporate access
Jennifer Kretzmann Retail investors +44 203 749 5824
US toll-free +1 866 381 72 77
Adrian Kemp
Company Secretary
AstraZeneca PLC
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
END
TVRFLFSFLFIFIII
(END) Dow Jones Newswires
January 02, 2020 10:00 ET (15:00 GMT)
Astrazeneca (LSE:AZN)
Historical Stock Chart
From Apr 2024 to May 2024
Astrazeneca (LSE:AZN)
Historical Stock Chart
From May 2023 to May 2024